This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Another Rescue Therapy Option for Patients with Moderate-to-Severe Asthma

List of authors.
  • Michael Schatz, M.D.

Since the initial guidelines of the National Asthma Education and Prevention Program (NAEPP) were published in 1991,1 short-acting β2-agonists (SABAs) have been recommended as the preferred rescue therapy for patients with asthma of any severity. In the 2020 NAEPP update,2 for the first time, two additional forms of rescue therapy were recommended: an as-needed SABA inhaler paired with a separate inhaled glucocorticoid for patients with mild asthma and a single inhaler containing glucocorticoid–formoterol for patients receiving maintenance therapy with an inhaled glucocorticoid–formoterol combination (single maintenance and reliever inhaler therapy [SMART]) for moderate-to-severe asthma. In this issue of the Journal, Papi . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Department of Allergy, Kaiser Permanente Southern California, San Diego.